Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming ANAVEX®3-71 Clinical Cardiovascular Safety

<p>NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced a peer-reviewed publication in Clinical Pharmacology […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/anavex-life-sciences-reports-publication-of-anavex3-71-in-clinical-journal-confirming-anavex3-71-clinical-cardiovascular-safety/">Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming ANAVEX®3-71 Clinical Cardiovascular Safety</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>